HIV grants almost twice as likely to be changed as other NIH grants
Dr Jade Pagkas-Bather received her first grant from the National Institutes of Health in June 2025 to test whether monthly $500 cash grants would help poor, HIV-positive young people in Chicago stay on treatment. She had cleared peer review and was about to be funded when NIH program officers began asking for changes on video calls, she said.
Program officers asked her team to drop the term “gender identities” from a commitment to include people of all gender identities, and to remove a clause stating that Black and Latinx people experience more poverty than other people, Pagkas-Bather said. They also raised “concern” about the acronym for basic income grants, Big.
“Maybe taking care of your HIV isn’t your priority when you’re unhoused or hungry,” Pagkas-Bather said of her hypothesis.
She made the edits, received funding and enrolled dozens of participants. In 2026, a larger demand arrived. Pagkas-Bather recounted being told: “You can’t use unconditional cash transfer and you need to remove any reference to this having an impact on policy.”
Data shared exclusively with The Guardian shows renegotiations surged in the first two years of the Trump administration. In 2023, 154 of more than 40,000 grants up for renewal changed their titles, abstracts or public health statements — 0.4% of all grants, according to Grant Witness. In 2025, 8.6% of continuing grants changed year-to-year, more than 3,401 of the more than 39,000 grant continuations awarded by NIH. In 2026, 8.5% changed, or 3,006 of the agency’s nearly 35,500 grants. That is a 21-fold increase over the 2023 rate.
In the 2027 fiscal year, which has just started, 64 grants have been renewed and three have already seen changes. One study initially titled “The Black Zones”, focused on African American neighborhoods, had all mentions of “African Americans” removed in favor of “Black Americans”. Another HIV grant studying a specific viral subtype changed text from “men and women” to “a wide range of people”.
HIV grants are almost twice as likely to have been changed, and were especially hard-hit in early cancelations, the data shows. In 2025, 305 of 1,795 HIV-related continuing grants changed, or 17%. In 2026, 335 of 1,609 grant continuations changed, or 20.8%. The Guardian reported that many of those renegotiations likely followed the administration’s severe restrictions on scientific work in South Africa.
Jeremy Berg, former director of the National Institute of General Medical Sciences, has closely tracked changes in NIH grant-making. “The censorship that’s happening now is, I think, pretty much unprecedented,” Berg said. “It’s very Orwellian in the sense that it’s purely double-speak,” he added. “It’s a way of exerting political control and control of the terms of the debate.”
The NIH process was set into motion in 2025, after court battles slowed grant cancellations. As the administration sought to change scientific studies, it developed a process for bringing grants into “alignment” with priorities that include the belief that gender is binary and that research into health equity is “unscientific”. The review uses a “text analysis tool” to flag grants, and NIH director Jay Bhattacharya has repeatedly denied that a list of banned words exists.
The Guardian asked the NIH how many grants had been changed and about the text-analysis tool. The agency said “more than 5,000 new and continuation grants” have been renegotiated “to ensure the agency funds the most meritorious science, addresses urgent health needs, and sustains a robust biomedical research workforce”.
“During these grant renegotiations, grant scopes were substantively altered wherever possible to replace poorly defined, non-scientific or subjective concepts and variables with well-defined, scientific concepts that have objective and measurable variables,” an NIH spokesperson told The Guardian. “Renegotiation is a normal process that NIH has used for years on grants for various reasons. All renegotiated grants are assessed by human experts.”
Sarah Kobrin, a National Cancer Institute branch chief, said program officers often intuit what might get flagged. “They are told to contact the investigators in case the investigators want to make changes,” Kobrin said. “We are compelled. We are not calling and saying, ‘Hey, could you change these words.’” Instead, she said, officers tell investigators: “Hey, you know, if you want, you could change these words and it might work out well for you.” Kobrin added: “It is certainly, certainly, certainly continuing.”
The number of scientists who have been through the process is unknown. “Her story is not unique,” said Shalini Agarwal of Project Democracy, which represents Pagkas-Bather in a suit seeking class-action status and alleging the government is violating the first amendment. “There are many other researchers in a similar situation who are being asked to subvert their own grant projects that have been peer-reviewed and approved for funding a year or more into the project.”
Pagkas-Bather is one of 14 named plaintiffs in the lawsuit, which argues that renegotiations and cancellations amount to censorship or, in legalese, “viewpoint-based discrimination”. The Guardian has also reported on researchers in Pittsburgh whose funding for a study of Alzheimer’s disease risk in a low-income, majority Black neighborhood was cut. The study was cancelled by the administration, leaving hundreds of aging residents without potential dementia diagnoses.
Ultimately, Pagkas-Bather was told that if she did not remove the cash payments from her $1.3m grant, she would need to find $1m in funding elsewhere. She eliminated the cash grants and plans to use food and transportation vouchers instead, which means asking each participant for consent again because the study they signed up for bears little resemblance to the one she is now conducting.
Leslie McGorman, senior director of policy and strategy with AIDS United, said the study’s premise is what makes it a target. “Not only would [Pagkas-Bather’s study] demonstrate that money empowers people to preserve their right to exist, but also thrive,” McGorman said. “That is so threatening to this administration.”
A federal court hearing in November will decide whether the lawsuit filed by Pagkas-Bather and the other plaintiffs receives class-action status. As a historic number of Democratic doctors and scientists prepare to take office, current and former NIH leaders said Congress has years of work ahead to restore the agency.